Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$839.4m

Capricor Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Capricor Therapeutics has a total shareholder equity of $68.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $93.0M and $24.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$85.03m
EquityUS$68.26m
Total liabilitiesUS$24.69m
Total assetsUS$92.95m

Recent financial health updates

Recent updates

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Financial Position Analysis

Short Term Liabilities: CAPR's short term assets ($85.8M) exceed its short term liabilities ($20.5M).

Long Term Liabilities: CAPR's short term assets ($85.8M) exceed its long term liabilities ($4.2M).


Debt to Equity History and Analysis

Debt Level: CAPR is debt free.

Reducing Debt: CAPR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CAPR has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 20.6% each year.


Discover healthy companies